Lead Plaintiff Deadline: May 24, 2022
Please Upload related files below
Fill in below.
Looking for more?
(i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Homology, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Homology, if applicable.
If you suffered a loss in Homology during the relevant time frame, or pursuant to Homology’s IPO if listed above, you have until May 24, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.